APLS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
APLS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-05-14), Apellis Pharmaceuticals's share price is $16.70. Apellis Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.
The historical rank and industry rank for Apellis Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:
As of today (2025-05-14), Apellis Pharmaceuticals's share price is $16.70. Apellis Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.79. Therefore, Apellis Pharmaceuticals's PE Ratio (TTM) for today is At Loss.
As of today (2025-05-14), Apellis Pharmaceuticals's share price is $16.70. Apellis Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.78. Therefore, Apellis Pharmaceuticals's PE Ratio without NRI for today is At Loss.
The historical data trend for Apellis Pharmaceuticals's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apellis Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Price-to-Owner-Earnings | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Apellis Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Price-to-Owner-Earnings | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Apellis Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Apellis Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Apellis Pharmaceuticals's Price-to-Owner-Earnings falls into.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Apellis Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as
Price-to-Owner-Earnings | = | Share Price | / | Owner Earnings per Share (TTM) |
= | 16.70 | / | -1.02 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apellis Pharmaceuticals (NAS:APLS) Price-to-Owner-Earnings Explanation
For how to get Owner Earnings per Share (TTM), please click.
Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
James George Chopas | officer: See Remarks | 950 WINTER STREET, WALTHAM MA 02451 |
David O. Watson | officer: General Counsel | 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Mark Jeffrey Delong | officer: Senior Vice President | 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Adam J. Townsend | officer: See Remarks | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Pascal Deschatelets | officer: Chief Operating Officer | 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Karen Lewis | officer: Chief People Officer | APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Jeffrey Eisele | officer: See Remarks | APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Nur Nicholson | officer: Chief Technical Officer | APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Timothy Eugene Sullivan | officer: Chief Financial Officer | 800 BOYLSTON ST., SUITE 3310, PRUDENTIAL TOWER C/O AJU IB INVESTMENT, BOSTON MA 02199 |
Cedric Francois | director, 10 percent owner, officer: Chief Executive Officer | 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Caroline Baumal | officer: Chief Medical Officer | C/O APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
A. Sinclair Dunlop | director | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Lukas Scheibler | officer: See Remarks | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Alec Machiels | director | 505 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10022 |
Federico Grossi | officer: See Remarks | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
From GuruFocus
By GuruFocus News • 03-01-2025
By Marketwired • 02-24-2025
By GuruFocus News • 02-21-2025
By GuruFocus News • 04-21-2025
By GuruFocus News • 03-01-2025
By Marketwired • 01-13-2025
By GuruFocus News • 04-21-2025
By GuruFocus News • 01-13-2025
By GuruFocus News • 03-01-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.